TPMT -Cisplatin: Lessons in Citation Integrity and Scientific Oversight
JCO Oncology Practice · 2026-11 · 22 (11) · 2001-2008
DOI: 10.1200/op-25-00913 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2026-11. Verfasst von Youngwoo Cho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Cisplatin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To assess the ongoing citation of the 2009 Nature Genetics article by Ross et al linking TPMT to cisplatin-induced ototoxicity and to evaluate the extent to which its disputed findings persist in the literature. METHODS A total of 378 Google Scholar citations of the 2009 Nature Genetics publication from 2009 to 2025 were examined, of which 214 PubMed-indexed manuscripts were screened and categorized by citation nuance (positive, negative/mixed) and citation characteristics using the framework proposed by Suelzer et al in a 2019 JAMA Network Opens study. Citation context was independently assessed by two reviewers, with discrepancies resolved by consensus of all three authors. RESULTS Most articles cited the 2009 publication in a favorable or uncritical manner, even in publications after 2015 US Food and Drug Administration's cisplatin label revision acknowledging that the 2009 findings were flawed. A minority of citations acknowledged conflicting evidence or questioned the study's validity. CONCLUSION Although the 2009 publication's findings have been widely challenged, many subsequent authors continue to cite the study without acknowledging its limitations. This pattern highlights the need for stronger postpublication oversight, more transparent editorial practices by high-impact journals, and greater critical engagement by authors when citing foundational literature to ensure that clinical and research narratives are shaped by reliable and current evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL.
- Center for Personalized Therapeutics, University of Chicago, Chicago, IL.
- Department of Medicine, University of Chicago Medical Center and Biological Sciences, Chicago, IL.
ORCID-Profile: Youngwoo Cho, Thomas Chen, Mark J Ratain
Zitieren
APA
Cho, Y., Chen, T., & Ratain, M. J. (2026). TPMT -Cisplatin: Lessons in Citation Integrity and Scientific Oversight. JCO Oncology Practice, 22(11), 2001-2008. https://doi.org/10.1200/op-25-00913
Vancouver
Cho Y, Chen T, Ratain MJ. TPMT -Cisplatin: Lessons in Citation Integrity and Scientific Oversight. JCO Oncology Practice. 2026;22(11):2001-2008. doi:10.1200/op-25-00913
BibTeX
@article{Cho2026,
author = {Cho, Youngwoo and Chen, Thomas and Ratain, Mark J},
title = {TPMT -Cisplatin: Lessons in Citation Integrity and Scientific Oversight},
journal = {JCO Oncology Practice},
year = {2026},
volume = {22},
number = {11},
pages = {2001--2008},
doi = {10.1200/op-25-00913}
}
EUVIMED